News
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback